Title Evaluation of ECM Hydrogel as a Treatment for Stroke Injury
Description: Products composed of mammalian Extracellular Matrix (ECM) have been regulated as a “device” by the FDA, and these materials have been used as a bioscaffold for the repair and reconstruction of soft tissues for the past 15 years. Work in the Badylak laboratory has shown that such matrix materials, when properly prepared, can minimize fibrous tissue deposition and induce a constructive and functional tissue remodeling response. This constructive response is due, at least in part, to bioactive cryptic peptides created during the process of scaffold degradation. Bioactive properties of these oligopeptides include chemoattraction for endogenous stem and progenitor cells, angiogenesis, and modulation of the innate immune response toward a regulatory and constructive “M2”phenotype.